Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation

被引：10

作者：

Miyauchi, Shunsaku ^{[1
]}

Shien, Kazuhiko ^{[1
]}

Takeda, Tatsuaki ^{[2
]}

Araki, Kota ^{[1
]}

Nakata, Kentaro ^{[1
]}

Miura, Akihiro ^{[1
]}

Takahashi, Yuta ^{[1
]}

Kurihara, Eisuke ^{[1
]}

Ogoshi, Yusuke ^{[1
]}

Namba, Kei ^{[1
]}

Suzawa, Ken ^{[1
]}

Yamamoto, Hiromasa ^{[1
]}

Okazaki, Mikio ^{[1
]}

Soh, Junichi ^{[1
]}

Tomida, Shuta ^{[4
]}

Yamane, Masaomi ^{[1
]}

Sakaguchi, Masakiyo ^{[3
]}

Toyooka, Shinichi ^{[1
]}

机构：

[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Breast & Endocrinol Surg, Okayama, Japan

[2] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Clin Pharm, Okayama, Japan

[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Cell Biol, Okayama, Japan

[4] Okayama Univ Hosp, Ctr Comprehens Genom Med, Okayama, Japan

来源：

ANTICANCER RESEARCH | 2020年 / 40卷 / 05期

关键词：

Pan-RAF inhibitor; LY3009120; non-small cell lung cancer; BRAF mutation; DABRAFENIB PLUS TRAMETINIB; PRECLINICAL MODELS; OPEN-LABEL; FEATURES; RESISTANCE;

D O I：

10.21873/anticanres.14237

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The therapeutic strategy for patients with non-small-cell lung cancer (NSCLC) harboring the BRAF non-V600E mutation has not been established. LY3009120, a newly discovered pan-RAF inhibitor, has shown strong antitumor effects in cancers with various BRAF genotypes. This study investigated the antitumor effects of LY3009120 in NSCLC cells harboring the BRAF non-V600E mutation. Materials and Methods: We examined the antitumor effects of LY3009120 by MTS assay and flow cytometry. We analyzed the expression status of proteins by western blot. The mouse xenograft models were used for the in vivo experiments. Results: LY3009120 suppressed BRAF-related downstream pathway molecules and induced cleavage of poly ADP-ribose polymerase in all examined NSCLC cell lines. LY3009120 also inhibited in vivo tumor growth in NSCLC cells harboring the BRAF non-V600E mutation. Conclusion: LY3009120 is a potent therapeutic agent for patients with BRAF non-V600E mutant NSCLC.

引用

页码：2667 / 2673

页数：7

共 50 条

[1] Novel oncogenic BRaf deletions functioning as BRaf homodimer and sensitive to inhibition by LY3009120, a pan Raf and Raf dimer inhibitor
Chen, Shih-Hsun
Buchanan, Sean
Zhang, Youyan
Van Horn, Robert
Yin, Tinggui
Yadav, Vipin
Wong, Swee Seong
Huber, Lysiane
Henry, James
Conti, Ilaria
Starling, James J.
Plowman, Gregory D.
Peng, Sheng-Bin
CANCER RESEARCH, 2015, 75
[2] A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Sullivan, Ryan J.
Hollebecque, Antoine
Flaherty, Keith T.
Shapiro, Geoffrey I.
Ahnert, Jordi Rodon
Millward, Michael J.
Zhang, Wei
Gao, Ling
Sykes, Amanda
Willard, Melinda D.
Yu, Danni
Schade, Andrew E.
Crowe, KrisAnne
Flynn, Daniel L.
Kaufman, Michael D.
Henry, James R.
Peng, Sheng-Bin
Benhadji, Karim A.
Conti, Ilaria
Gordon, Michael S.
Tiu, Ramon V.
Hong, David S.
MOLECULAR CANCER THERAPEUTICS, 2020, 19 (02) : 460 - 467
[3] Combination effect of low dose Cytarabine and pan-RAF inhibitor LY3009120 in AML cells with RAS mutations
Park, Jihyun
Yoon, Sung-Soo
Koh, Youngil
CANCER RESEARCH, 2019, 79 (13)
[4] Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
Chen, Shih-Hsun
Zhang, Youyan
van Horn, Robert D.
Yin, Tinggui
Buchanan, Sean
Yadav, Vipin
Mochalkin, Igor
Wong, Swee Seong
Yue, Yong Gang
Huber, Lysiane
Conti, Ilaria
Henry, James R.
Starling, James J.
Plowman, Gregory D.
Peng, Sheng-Bin
CANCER DISCOVERY, 2016, 6 (03) : 300 - 315
[5] Evaluation of Pan-RAF Inhibitor LY3009120 on Human Uveal Melanoma Cell Line 92-1
Gao, Yu
Wendt, Sophia
Krohn, Saskia
Alammar, Moosheer
Junghanss, Christian
Nolte, Ingo
Escobar, Hugo Murua
ANTICANCER RESEARCH, 2024, 44 (09) : 3843 - 3848
[6] Identification of LY3009120 as a pan inhibitor of Raf isoforms and dimers with minimal paradoxical activation and activities against BRaf or Ras mutant tumor cells
Peng, Sheng-Bin
Henry, James
Kaufman, Michael
Lu, Wei-Ping
Smith, Bryan D.
Vogeti, Subha
Wise, Scott
Zhang, Youyan
Van Horn, Robert
Zhang, Xiaoyi
Yin, Tinggui
Yadav, Vipin
Huber, Lysiane
Kays, Lisa
Walgren, Jennie
McCann, Denis
Patel, Phenil
Buchanan, Sean
Conti, Ilaria
Starling, James J.
Flynn, Daniel L.
CANCER RESEARCH, 2014, 74 (19)
[7] Anti-Tumor Effect of Pan-RAF Inhibitor in NSCLC Cells Harboring BRAF Mutation
Miyauchi, S.
Shien, K.
Araki, K.
Nakata, K.
Miura, A.
Namba, K.
Suzawa, K.
Yamamoto, H.
Okazaki, M.
Tomida, S.
Toyooka, S.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S423 - S424
[8] Pan-RAF inhibitor LY3009120 is highly synergistic with low-dose cytarabine, but not azacitidine, in acute myeloid leukemia with RAS mutations
Park, Jihyun
Park, Hyejoo
Byun, Ja Min
Hong, Junshik
Shin, Dong-Yeop
Koh, Youngil
Yoon, Sung-Soo
ONCOLOGY LETTERS, 2021, 22 (05)
[9] A pan-RAF inhibitor LY3009120 inhibits necroptosis by preventing phosphorylation of RIPK1 and alleviates dextran sulfate sodium (DSS)-induced colitis
Zhang, C.
Luo, Y.
He, Q.
Liu, S.
He, A.
Yan, J.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 639 - 639
[10] A pan-RAF inhibitor LY3009120 inhibits necroptosis by preventing phosphorylation of RIPK1 and alleviates dextran sulfate sodium-induced colitis
Zhang, Chong
Luo, Yiqin
He, Qiaoling
Liu, Shuai
He, Andong
Yan, Jie
CLINICAL SCIENCE, 2019, 133 (08) : 919 - 932

← 1 2 3 4 5 →